How to Choose the Right CDMO for Small Molecule Drug Substance Manufacturing in 2026
How to Choose the Right CDMO for Small Molecule Drug Substance Manufacturing in 2026
Description: Learn how to evaluate a small molecule CDMO based on process chemistry, scale-up capability, HPAPI containment, integrated GMP manufacturing, and regulatory track record.
Published market estimates vary by scope. One 2026 report covering both small-molecule APIs and drug products estimated the global small-molecule CMO/CDMO market at USD 54.42 billion in 2025 and USD 58.55 billion in 2026, up 7.6%. That expansion reflects the continuing importance of outsourcing across pharmaceutical development and manufacturing
For sponsors choosing a CDMO, however, market growth is only part of the picture. Scale-up performance, technology transfer, HPAPI containment, and regulatory readiness can have a much more direct impact on development timelines. This guide explains how to evaluate these capabilities and what evidence to request before selecting a small-molecule drug substance manufacturing partner.
Technical Fit Starts with Chemistry and Scale-Up
Chemistry comes first. Not every CDMO can handle the molecules sitting in your pipeline. The FDA reported 46 novel drug approvals in 2025, with a 2026 review identifying 31, or 67.4%, as small molecules. The trend continued into 2026, with FDA approvals including orforglipron, an oral small-molecule GLP-1 receptor agonist, and vepdegestrant, the first approved PROTAC drug. Many small-molecule programs involve multi-step synthesis, cryogenic reactions, stereoselective catalysis, or difficult impurity control. Sponsors should therefore look for project experience relevant to their specific chemistry rather than broad capability lists.
Scale-up is the next test. A partner who delivers grams for your IND might struggle at kilo or ton scale because crystallization, heat transfer, mixing, and impurity profiles can change as equipment and batch size increase. Useful evidence includes redacted scale-up case studies, representative batch-performance summaries, and consistency in yield, impurity and critical-process-parameters between lab and plant runs.
Regulatory history shows how the quality system performs under external scrutiny. A recent, relevant FDA cGMP inspection that concluded without the issuance of a Form FDA 483, followed by receipt of the Establishment Inspection Report (EIR), can be a positive indicator of quality-system maturity. Experience supporting more than 150 US–China dual IND filings can also demonstrate familiarity with multi-jurisdictional CMC requirements.
The following checklist summarizes the evidence sponsors should request before selecting a CDMO partner.
| Evaluation Dimension | What to Ask For | Signals Capability | Signals Risk |
|---|---|---|---|
| Process chemistry | Project list in your molecule class | Published synthetic routes, patents | Generic capability charts |
| Scale-up feasibility | Redacted scale-up evidence and representative batch-performance summaries | Consistent yield lab-to-plant | "We can scale anything" |
| HPAPI containment | OEB classification, SMEPAC data | OEB-4/5 isolators, surrogate testing | "We handle potent compounds" |
| Regulatory track record | Recent inspection history, Form FDA 483 status, EIR or inspection classification where available, and audit follow-up records | Relevant FDA inspection with no Form FDA 483 issued and EIR received; successful EU QP qualification audit with documented closure of observations | Certificates only, no recent audits |
| Integration depth | Single quality system, dedicated PM | Route-to-GMP under one roof | Departmental silos, multiple MSAs |
HPAPI Capability Requires Containment Evidence
Highly potent API (HPAPI) manufacturing requires compound-specific exposure assessment and containment controls. Depending on the compound's OEL, physical form, and process operations, this may involve closed handling, isolator technology, validated cleaning procedures, and containment-performance verification.
An OEB label alone does not establish that a facility is suitable for every HPAPI.
The following OEB ranges are commonly used as a reference:
| OEB Category | OEL (µg/m³) | Containment Approach | Representative Equipment |
|---|---|---|---|
| OEB 1–2 | > 100 | Standard GMP, open handling | Fume hoods, laminar flow booths |
| OEB 3 | 10–100 | Enhanced ventilation, local containment | Weighing isolators, LEV systems |
| OEB 4 | 1–10 | Closed systems, isolator-based transfer | Glove boxes, split butterfly valves |
| OEB 5 | < 1 | Full isolation; dedicated or appropriately qualified shared equipment based on risk assessment | Continuous liner isolators, OEB-5 suites |
OEB definitions are not globally harmonized. Facility suitability should be assessed using the compound-specific OEL/ADE, physical form, dustiness, process scale, and task-based exposure data.
Analytical capability also matters. An ADE/PDE-based MACO may result in a surface-residue acceptance limit below the validated quantitation capability of the swab or rinse method. In this situation, “below LOQ” may not be sufficient, and the sponsor and CDMO may need to improve method sensitivity, revise sampling, introduce dedicated equipment, or redesign the process.
Strong containment programs therefore use evidence such as SMEPAC testing across representative operations including charging, sampling, milling, and filter discharge, surrogate testing data, and exposure assessments rather than equipment specifications alone.
Complex chiral chemistry requires similar scrutiny. For molecules such as Eribulin, which contains 19 chiral centers, published synthetic routes, reproducible stereochemical control, and demonstrated scale-up performance provide stronger evidence than general chemistry claims.
Integrated Development Reduces Technology-Transfer Risk
Drug substance programs often encounter problems at the handoff between route scouting, process development, analytical development, and GMP manufacturing.
An integrated CDMO can reduce these interfaces by coordinating:
This becomes more important as manufacturing scale increases.
Typical requirements also change across development:
| Development Phase | Typical Batch Size | GMP Standard | Primary Risk Focus |
|---|---|---|---|
| Preclinical / IND-enabling | Milligrams–grams | Non-GMP to GMP | Route viability, impurity identification |
| Phase I | Grams–kilograms | Phase-appropriate GMP controls, according to the applicable jurisdiction | Crystallization reproducibility |
| Phase II–III | Multi-kilograms | GMP with increasing process definition, analytical validation and stability support | Scale-up consistency, stability data |
| Commercial | Tens of kg–tons | Commercial GMP, process validation and lifecycle control | Supply continuity, cost of goods |
These ranges are illustrative and program-specific. Where manufacturing sites, equipment, or scale must change, the CDMO should also have established procedures for comparability assessment, analytical transfer, change control, and process validation.
Regulatory History Shows How the Quality System Performs
Certifications alone provide limited insight into how a CDMO performs under regulatory scrutiny.
Sponsors should review recent, site-relevant evidence, including:
An FDA cGMP inspection that concludes without the issuance of a Form FDA 483, followed by receipt of the EIR, can be a positive indicator of quality-system maturity.
The same principle applies to EU QP audits and pre-approval inspections: results should be evaluated together with the inspected site, product scope, quality system, and response to previous observations rather than treated as stand-alone credentials.
ChemExpress Provides Verifiable Evidence Across Key Selection Criteria
According to publicly disclosed project and regulatory information, ChemExpress provides several examples of the evidence sponsors can request when evaluating a small-molecule CDMO:
These examples show why CDMO selection should be based on project experience, containment performance, scale-up evidence, and site-specific regulatory history rather than broad capability claims.
FAQ
Q1: What is the difference between an API and a drug substance?
A: In small-molecule pharmaceutical development, “active pharmaceutical ingredient” and “drug substance” are generally used interchangeably. “Drug substance” is common in CTD and regulatory CMC documentation, while “API” is widely used in GMP guidance, manufacturing and commercial communication. The complete production chain flows from regulatory starting materials (RSMs) through intermediates to the API/drug substance, which then gets formulated into the drug product. When evaluating a CDMO, ensure appropriate control across the supply chain, with GMP applied from the justified API starting-material introduction point onward in accordance with the development stage, regulatory strategy and ICH Q7 expectations.
Q2: How do I evaluate a CDMO's HPAPI manufacturing capability?
A: Go beyond the marketing claim of "HPAPI-capable." Ask for their OEB classification system and the specific containment level of their production lines. Request SMEPAC testing data for representative operations—charging, sampling, milling, and filter discharge. Verify that their cleaning validation approach accounts for ADE/PDE-driven limits, not just visual cleanliness. Check whether they have dedicated equipment for the most potent compounds, and ask how they handle the scenario where the cleaning limit falls below the analytical method's LOQ. A CDMO with OEB-5 isolators and a documented track record in targeted anti-tumor drug manufacturing should be able to answer these questions directly.
Q3: What scale of GMP manufacturing do I need for clinical-stage supply?
A: It depends on your development phase and dosing regimen. Phase I typically requires gram-to-kilogram quantities; Phase II–III may need multi-kilogram batches; commercial supply can range from tens of kilograms to multi-ton production. A CDMO should demonstrate a credible scale-up and technology-transfer strategy across development stages. Where site or equipment changes are required, the partner should have established procedures for process comparability, analytical transfer, change control and validation. Look for partners who offer GMP manufacturing from milligrams to tons, with dedicated project teams managing the transition between phases. This can reduce avoidable transfer delays and helps maintain control of critical process parameters as the process moves across scales, equipment and development stages.
Q4: How long does technology transfer typically take?
A: There is no universal industry-standard duration for pharmaceutical technology transfer. Timing depends on process complexity, documentation completeness, facility and equipment fit, analytical-method readiness, containment requirements, material availability, and the extent of qualification or validation required. WHO guidance emphasizes a planned, documented and risk-based transfer process, including gap analysis, defined responsibilities, training, process transfer, analytical transfer and successful transfer verification.[8] Sponsors should therefore request a project-specific transfer plan rather than rely on a generic month-based estimate.
Q5: What regulatory history, inspection outcomes and quality-system evidence should I review when evaluating a small-molecule CDMO?
A: Prioritize recent, site-relevant inspection outcomes over certifications alone. Review the Form FDA 483 status, receipt of the EIR, EU QP audit results, inspection scope and broader compliance history. Also assess the CDMO’s experience supporting IND/NDA filings and its record in client and third-party audits. ChemExpress, for example, has disclosed an FDA cGMP inspection at its drug-substance site and a 2026 FDA pre-approval inspection at its drug-product subsidiary, 2Y-Biopharma; both concluded without the issuance of a Form FDA 483 and were followed by receipt of the EIR. Such site-specific, verifiable evidence is more meaningful than general compliance claims.
References
[1] The Business Research Company. Small Molecule CMO/CDMO Global Market Report 2026. Published February 12, 2026.
[2] U.S. Food and Drug Administration. Novel Drug Approvals for 2025.
[3] U.S. Food and Drug Administration. FDA Approves First New Molecular Entity Under National Priority Voucher Program: orforglipron. April 1, 2026.
[4] U.S. Food and Drug Administration. FDA approves vepdegestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. May 1, 2026.
[5] European Medicines Agency. Guideline on setting health-based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities. EMA/CHMP/CVMP/SWP/169430/2012.
[6] International Society for Pharmaceutical Engineering. Good Practice Guide: Assessing the Particulate Containment Performance of Pharmaceutical Equipment (SMEPAC).
[7] International Council for Harmonisation. ICH Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients.
[8] World Health Organization. WHO Technical Report Series No. 961, Annex 7: WHO guidelines on transfer of technology in pharmaceutical manufacturing.
[9] U.S. Food and Drug Administration. Inspectional Observations and Citations (Form FDA 483 information).
[10] U.S. Food and Drug Administration. Guidance for Industry: CGMP for Phase 1 Investigational Drugs.
[11] WIPO Patent Publication WO2024092420A1. Preparation method for ((2R,7aS)-2-fluorohexahydro-1H-pyrrolizin-7a-yl)methanol.
[12] European Medicines Agency. QP declaration guidance and questions and answers on third-party audits.
[13] International Council for Harmonisation. ICH Q3A(R2): Impurities in New Drug Substances.
[14] International Council for Harmonisation. ICH Q1A(R2): Stability Testing of New Drug Substances and Products.